Artelo Biosciences Proxy Statement Filed for Dec 19 Meeting

TL;DR

Artelo Bio proxy out for Dec 19 meeting - vote on directors & auditors.

AI Summary

Artelo Biosciences, Inc. filed its definitive proxy statement on November 8, 2024, for its annual meeting of stockholders scheduled for December 19, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but the specific proposals and company performance can introduce varying levels of risk.

Key Numbers

• 20241219 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
• 20241108 — Filing Date (Date the definitive proxy statement was filed with the SEC.)

Key Players & Entities

• ARTELO BIOSCIENCES, INC. (company) — Registrant
• 0001621221 (company) — Central Index Key
• 20241108 (date) — Filing Date
• 20241219 (date) — Meeting Date

FAQ

Filing Documents

• artl_def14a.htm (DEF 14A) — 424KB
• artl_def14aimg5.jpg (GRAPHIC) — 5KB
• artl_def14aimg6.jpg (GRAPHIC) — 5KB
• artl_def14aimg7.jpg (GRAPHIC) — 22KB
• artl_def14aimg8.jpg (GRAPHIC) — 20KB
• 0001640334-24-001670.txt ( ) — 497KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 6 Corporate Governance 7 Executive Officers 16

Executive Compensation

Executive Compensation 17 Pay vs Performance 19 Proposal 1 – Election of Directors 21 Proposal 2 – Ratification Of Independent Registered Public Accounting Firm 22 Report of the Audit Committee 23 Related Person Transactions 24 Other Matters 25 Table of Contents 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 2024 PROXY STATEMENT General Information The Board of Directors (the "Board") of Artelo Biosciences, Inc., a Nevada corporation ("Artelo," "Artelo Biosciences," "the company," "we," "us" or "our") has delivered these proxy materials to you in connection with the solicitation of proxies for use at the 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting will be held live via internet webcast on Friday, December 20, 2024, at 8:00 a.m., Pacific Time, or at any adjournment or postponement thereof, for the purposes stated herein. These proxy materials were first sent or given on or about November 8, 2024, to all stockholders as of the record date. Proxy Materials The Notice of Internet Availability of Proxy Materials containing instructions on how to access this proxy statement, the accompanying notice of annual meeting and form of proxy, and our annual report, is first being sent or given on or about November 8, 2024, to all stockholders of record as of November 8, 2024. The proxy materials and our annual report can be accessed as of November 8, 2024, by visiting https://www.proxyvote.com/. If you receive a Notice of Internet Availability, then you will not receive a printed copy of the proxy materials or our annual report in the mail unless you specifically request these materials. Instructions for requesting a printed copy of the proxy materials and our annual report are set forth in the Notice of Internet Availability. Virtual Annual Meeting We are embracing technology to provide expanded access, improved communication, reduced environmental impact and cost savings for our stockholders and the C

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table presents certain information with respect to the beneficial ownership of our common stock as of November 8, 2024, by (i) each person we know to be the beneficial owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and our directors and (iii) all executive officers and directors as a group. Information with respect to beneficial ownership is based on a review of our stock transfer records and on Schedules 13D and 13G that have been filed with the SEC by or on behalf of the stockholders listed below. Except as indicated by the footnotes below, we believe, based on the information available to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community property laws. Percentage of beneficial ownership is calculated based on [3,227,700] shares of common stock outstanding on November 8, 2024. We have determined beneficial ownership in accordance with SEC rules. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed as outstanding shares of common stock subject to stock options held by that person that are currently exercisable or exercisable within 60 days of November 8, 2024. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Except otherwise indicated in the footnotes below, the address of each beneficial owner listed in the table is Artelo Biosciences, Inc., 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075. Number of Number of Shares Options and/or Warrants Exercisable Total Shares Beneficially Owned Name and Address of Beneficial Owner Shares Held within 60 Days Number % Directors and Named Executive Officers Gregory D.

View Full Filing

View this DEF 14A filing on SEC EDGAR